Member Info for Zoman

Mr. Dixon sold all of his remaining shares (2.5M) in FTC back in June 2025, however, Mrs Dixon had a holding of 20M shares at that time, she appears to have been reducing this of late hence the 8M currently held. RNS 6035M

Net. RNS 9163Y

The previously announced Board investigation and the independent, forensic review being undertaken by FRP Advisory continues to progress and the Board is hopeful that these will be concluded later this month. Trading in the Company's ordinary shares is anticipated to resume upon the publication of the Interim Results.

Net, from the RNS : 9659T 20 November 2019

Under the terms of the agreement, SkinBioTherapeutics' proprietary SkinBiotix™ platform will be paired with Croda's expertise in the development and commercialisation of unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market. Sederma, part of Croda International, is a specialist in bioactive ingredients for the cosmetic industry, and will be responsible for the development, manufacturing and commercialisation of the SkinBiotix™ technology. As design and build of the active ingredient is carried out there will be concurrent testing in focussed application areas which will be detailed in further, additional agreements.

Any licensed products resulting from this agreement will be sold to Croda's global portfolio of Personal Care customers. SkinBioTherapeutics will be paid tiered royalties based on global sales revenues on any licensed products derived from the partnership which will be subsequently agreed on successful development of the technology.

Sales and distribution rights are for the cosmetic sector alone, leaving SkinBioTherapeutics to focus on further applications of its technology in other sectors.